

**KENYA**  
**Support for Inactivated Polio Vaccine (IPV)**

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Kenya											
<b>2. Grant number(s):</b> 1518-KEN-25c-X / 15-KEN-08h-Y											
<b>3. Date of Decision Letter:</b> 23 March 2018											
<b>4. Date of the Partnership Framework Agreement:</b> 25 November											
<b>5. Programme title:</b> NVS, IPV routine											
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)											
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID											
<b>8. Programme duration<sup>2</sup>:</b> 2015 - 2018											
<p><b>9. Indicative Programme Budget:</b> (subject to the terms of the Partnership Framework Agreement, if applicable)  <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 20%; text-align: center;">2015-2017</th> <th style="width: 20%; text-align: center;">2018</th> <th style="width: 30%; text-align: center;">Total<sup>3</sup></th> </tr> </thead> <tbody> <tr> <td>Routine Programme (US\$)</td> <td style="text-align: center;">3,627,375<sup>4</sup></td> <td style="text-align: center;">1,171,000</td> <td style="text-align: center;">4,798,375</td> </tr> </tbody> </table>					2015-2017	2018	Total <sup>3</sup>	Routine Programme (US\$)	3,627,375 <sup>4</sup>	1,171,000	4,798,375
	2015-2017	2018	Total <sup>3</sup>								
Routine Programme (US\$)	3,627,375 <sup>4</sup>	1,171,000	4,798,375								
<b>10. Vaccine introduction grant / Product switch grant:</b> A VIG of US\$1,263,500 was paid on 7 <sup>th</sup> August 2015											
<p><b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable)<sup>5</sup></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 35%; text-align: left;">Number of vaccines to be purchased with Gavi funds</th> <th style="width: 30%; text-align: center;">2015-2017</th> <th style="width: 35%; text-align: center;">2018</th> </tr> </thead> <tbody> <tr> <td>IPV Routine Programme (doses)</td> <td></td> <td style="text-align: center;">1,412,000</td> </tr> </tbody> </table>				Number of vaccines to be purchased with Gavi funds	2015-2017	2018	IPV Routine Programme (doses)		1,412,000		
Number of vaccines to be purchased with Gavi funds	2015-2017	2018									
IPV Routine Programme (doses)		1,412,000									

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2018.

<sup>4</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>5</sup> This is the amount that Gavi has approved.

IPV Catch-up vaccination (doses)		
Annual Amounts (US\$)	US\$3,627,375	US\$1,171,000
<b>12. Procurement agency:</b> UNICEF.		
<b>13. Self-procurement:</b> Not applicable		
<b>14. Co-financing obligations:</b> Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Kenya is encouraged to contribute to vaccine and/or supply costs for IPV.		
<b>15. Operational support for catch-up campaigns:</b> Not applicable		
<b>16. Additional reporting requirements:</b>		
Reports and other information		Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.		15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable		
<b>18. Other conditions:</b> Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.		

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
23 March 2018

## KENYA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Kenya				
<b>2. Grant number:</b> 1819-KEN-12a-X / 08-KEN-08b-Y / 18-KEN-25a-Y				
<b>3. Date of Decision Letter:</b> 23 March 2018				
<b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014				
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine				
<b>6. Vaccine type:</b> Pneumococcal				
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 doses per vial, LIQUID, Pneumococcal (PCV10), 4 doses per vial, LIQUID				
<b>8. Programme duration<sup>1</sup>:</b> 2009 - 2019				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)				
	<b>2009-2017</b>	<b>2018</b>	<b>2019</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	183,605,453 <sub>3</sub>	3,475,500	14,409,500	201,490,453
<b>10. Vaccine introduction grant (in US\$) / Product Switch Grant:</b>				
<ul style="list-style-type: none"> <li>• A VIG of US\$443,500 was disbursed on 4<sup>th</sup> August 2010.</li> <li>• Kenya budgeted for a Switch grant totalling <b>US\$ 379,460</b> therefore this is the amount that will be disbursed to support with the costs of the product switch.</li> </ul>				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2009-2017</b>	<b>2018</b>		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

Number of Pneumococcal vaccines doses		1,032,800																		
Annual Amounts (US\$)	183,605,453 <sup>5</sup>	3,475,500																		
<p><b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>																				
<p><b>13. Self-procurement:</b> Not applicable</p>																				
<p><b>14. Co-financing obligations:</b> Reference code: 1819-KEN-12a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>99,600</td> <td>401,600</td> </tr> <tr> <td>Number of AD syringes</td> <td>67,300</td> <td>398,200</td> </tr> <tr> <td>Number of safety boxes</td> <td>750</td> <td>4,400</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>303,547</td> <td>1,224,847</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>308,500</td> <td>1,250,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2018	2019	Number of vaccine doses	99,600	401,600	Number of AD syringes	67,300	398,200	Number of safety boxes	750	4,400	Value of vaccine doses (US\$)	303,547	1,224,847	Total co-financing payments (US\$) (including freight)	308,500	1,250,500
Type of supplies to be purchased with Country funds in each year	2018	2019																		
Number of vaccine doses	99,600	401,600																		
Number of AD syringes	67,300	398,200																		
Number of safety boxes	750	4,400																		
Value of vaccine doses (US\$)	303,547	1,224,847																		
Total co-financing payments (US\$) (including freight)	308,500	1,250,500																		
<p><b>15. Operational support for campaigns:</b> Not applicable</p>																				
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> </tbody> </table>			Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018														
Reports and other information	Due dates																			
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018																			

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

Signed by,  
**On behalf of Gavi**

*Hind Khatib*

Hind Khatib-Othman  
Managing Director, Country Programmes  
23 March 2018

## KENYA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Kenya				
<b>2. Grant number:</b> 1819-KEN-04c-X				
<b>3. Date of Decision Letter:</b> 23 March 2018				
<b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014				
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine				
<b>6. Vaccine type:</b> Pentavalent				
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID				
<b>8. Programme duration<sup>1</sup>:</b> 2001 - 2019				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)				
	<b>2001-2017</b>	<b>2018</b>	<b>2019</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	168,223,947 <sup>3</sup>	1,447,500	3,402,000	173,073,447
<b>10. Vaccine introduction grant (in US\$):</b> A VIG of US\$50,000 was disbursed on 11 February 2002.				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2001-2017</b>	<b>2018</b>		
Number of Pentavalent vaccines doses		1,862,500		
Annual Amounts (US\$)	168,223,947 <sup>5</sup>	1,447,500		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.																				
<b>13. Self-procurement:</b> Not applicable																				
<p><b>14. Co-financing obligations:</b> Reference code: 1819-KEN-04c-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>403,000</td> <td>434,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>248,700</td> <td>385,400</td> </tr> <tr> <td>Number of safety boxes</td> <td>2,750</td> <td>4,250</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>302,089</td> <td>295,192</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>324,500</td> <td>324,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2018	2019	Number of vaccine doses	403,000	434,500	Number of AD syringes	248,700	385,400	Number of safety boxes	2,750	4,250	Value of vaccine doses (US\$)	302,089	295,192	Total co-financing payments (US\$) (including freight)	324,500	324,500
Type of supplies to be purchased with Country funds in each year	2018	2019																		
Number of vaccine doses	403,000	434,500																		
Number of AD syringes	248,700	385,400																		
Number of safety boxes	2,750	4,250																		
Value of vaccine doses (US\$)	302,089	295,192																		
Total co-financing payments (US\$) (including freight)	324,500	324,500																		
<b>15. Operational support for campaigns:</b> Not applicable																				
<b>16. Additional reporting requirements:</b>																				
Reports and other information		Due dates																		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.		15 May 2018																		
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat																		
<b>17. Financial clarifications:</b> Not applicable																				
<b>18. Other conditions:</b> Not applicable																				

Signed by,

**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
23 March 2018

## KENYA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Kenya				
<b>2. Grant number:</b> 1819-KEN-13b-X / 14-KEN-08b-Y				
<b>3. Date of Decision Letter:</b> 23 March 2018				
<b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014				
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine				
<b>6. Vaccine type:</b> Rotavirus				
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule				
<b>8. Programme duration<sup>1</sup>:</b> 2014 - 2019				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)				
	<b>2014-2017</b>	<b>2018</b>	<b>2019</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	22,383,421 <sub>3</sub>	4,079,500	5,383,000	31,845,921
<b>10. Vaccine introduction grant (in US\$):</b> A VIG of US\$1,218,500 was disbursed on 30 <sup>th</sup> June 2014				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2014-2017</b>	<b>2018</b>		
Number of Rotavirus vaccines doses		1,963,500		
Annual Amounts (US\$)	22,383,421 <sup>5</sup>	4,079,500		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.														
<b>13. Self-procurement:</b> Not applicable														
<p><b>14. Co-financing obligations:</b> Reference code: 1819-KEN-13b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>147,000</td> <td>250,500</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>295,637</td> <td>503,018</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>305,500</td> <td>519,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2018	2019	Number of vaccine doses	147,000	250,500	Value of vaccine doses (US\$)	295,637	503,018	Total co-financing payments (US\$) (including freight)	305,500	519,500
Type of supplies to be purchased with Country funds in each year	2018	2019												
Number of vaccine doses	147,000	250,500												
Value of vaccine doses (US\$)	295,637	503,018												
Total co-financing payments (US\$) (including freight)	305,500	519,500												
<b>15. Operational support for campaigns:</b> Not applicable														
<b>16. Additional reporting requirements:</b>														
Reports and other information		Due dates												
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.		15 May 2018												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat												
<b>17. Financial clarifications:</b> Not applicable														
<b>18. Other conditions:</b> Not applicable														

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
23 March 2018

## KENYA Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Kenya				
<b>2. Grant number:</b> 1819-KEN-06b-X				
<b>3. Date of Decision Letter:</b> 23 March 2018				
<b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014				
<b>5. Programme title:</b> NVS, Yellow Fever Routine				
<b>6. Vaccine type:</b> Yellow Fever				
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED				
<b>8. Programme duration<sup>1</sup>:</b> 2001 - 2019				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)				
	<b>2001-2017</b>	<b>2018</b>	<b>2019</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	496,374 <sup>3</sup>	44,000	69,500	609,874
<b>10. Vaccine introduction grant (in US\$):</b> A VIG of US\$50,000 was disbursed on 11 February 2002				
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable): <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2001-2017</b>	<b>2018</b>		
Number of Yellow Fever vaccines doses		38,000		
Annual Amounts (US\$)	496,374 <sup>5</sup>	44,000		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations: Reference code:** 1819-KEN-06b-X-C  
According to the co-financing policy, the Country falls within the group Preparatory transition.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019
Number of vaccine doses	600	5,400
Number of AD syringes	0	3,600
Number of re-constitution syringes	100	600
Number of safety boxes	0	50
Value of vaccine doses (US\$)	605	5,749
Total co-financing payments (US\$) (including freight)	1,000	6,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:**

There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

Signed by,  
**On behalf of Gavi**

*Hind A. Khatib*

Hind Khatib-Othman  
Managing Director, Country Programmes  
23 March 2018